The TIGIT/CD226 Axis Regulates Human T Cell Function

Ester Lozano, Margarita Dominguez-Villar, Vijay Kuchroo and David A. Hafler

J Immunol 2012; 188:3869-3875; Prepublished online 16 March 2012;
doi: 10.4049/jimmunol.1103627
http://www.jimmunol.org/content/188/8/3869

Supplementary Material
http://www.jimmunol.org/content/suppl/2012/03/16/jimmunol.1103627.DC1

References
This article cites 24 articles, 9 of which you can access for free at:
http://www.jimmunol.org/content/188/8/3869.full#ref-list-1

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
T cells are driven into cell cycle after TCR recognition of Ag presented by MHC and a second signal first elucidated with the CD80/CD86–CD28 costimulatory pathway (1). Although this has become a major tenant in immunology, it has become clear that there are a multitude of signals integrated by the T cell ultimately leading to either entry into cell cycle, expansion, and differentiation or to nonresponsiveness or apoptosis. Curiously, many of these costimulatory pathways have multiple receptor/ligand pairs, one of which results in positive signaling events while the other transmits negative signals, such as CD28/CTLA4 (2). A first step in deciphering how T cells integrate these second signals requires an understanding of the individual components of the costimulatory pathways.

Genome-wide association scans in patients with autoimmune diseases have identified allelic variants in a number of T cell costimulatory molecular pathways as genetic risk factors for disease pathogenesis. This includes allelic variants in the CTLA4/CD86 pathway (3–5) and CD226 that has been associated with risk to develop both type 1 diabetes and multiple sclerosis (MS) (6, 7). Costimulatory pathways regulate the functional outcome of T cell activation, and allelic variations altering the balance between positive and negative costimulatory signals may increase the risk of autoimmune diseases (2). These genetic investigations may be particularly useful in focusing on key nodal points that modulate immune response.

CD226 was first identified by Shibuya et al. (8, 9) as having a role in enhancing cytokotoxic function of NK cells, demonstrating that CD226 is associated with LFA-1 to induce IFN-γ production in naive CD4+ T cells. CD226 binds to two different cell surface ligands, CD155 (poliovirus receptor) and CD112 (10, 11). T cell Ig and ITIM domain (TIGIT) is a transmembrane glycoprotein belonging to a poliovirus receptor family of type 1 proteins that also binds to CD155 and CD112 ligands (12). TIGIT is expressed on peripheral memory and regulatory CD4+ T cells and NK cells and is upregulated following activation on naive CD4+ T cells. CD155 is a high-affinity receptor for TIGIT expressed on monocytes and CD11c+ human dendritic cells (DCs) (12). TIGIT contains an Ig-like V-type domain and an ITIM in its cytoplasmic domain, suggesting that receptor occupancy may trigger a negative signaling event. Similar to the costimulatory CD28/CTLA4–CD80/CD86 pathway where CD28 engagement induces positive and CTLA4 negative signaling while the CTLA4–CD28 pathway has been extensively investigated, little is known regarding the TIGIT/CD226 pathway, particularly in human T cells.

Grogan and colleagues (12) described that engagement of TIGIT by CD155 on human DCs enhanced the production of IL-10 while diminishing the production of IL-12p40. In addition to effects on APCs, we demonstrated a T cell-intrinsic inhibitory effect of TIGIT-dependent T cell signaling pathway in murine models of experimental autoimmune encephalomyelitis (EAE) (13). Specifically, we demonstrated that loss of TIGIT expression in mice results in hyperproliferative T cell responses and increased susceptibility to EAE. By generating an agonistic anti-TIGIT mAb, we showed that TIGIT directly inhibited murine T cell responses even in the absence of APCs, demonstrating a T cell intrinsic inhibitory effect of TIGIT.
Considering the potential importance of the TIGIT/CD226 pathway in human autoimmune disease and based on our murine studies (13), we investigated the specific role of TIGIT in human CD4+ T cell activation in the absence of APCs where CD155 expression on T cells provided a costimulatory signal. Using an agonistic anti-TIGIT mAb, we demonstrated a direct inhibitory effect on T cell proliferation with a decrease in expression of T-bet, GATA3, IFN regulatory factor (IRF)4, and retinoic acid-related orphan receptor c (RORE) with inhibition of cytokine production, predominantly IFN-γ. Knockdown of TIGIT expression by short hairpin (sh)RNA expression constructs introduced into human CD4+ T cells resulted in an increase of both T-bet and IFN-γ mRNA and protein expression. These effects could be overcome by blocking CD226 signaling, indicating that TIGIT exerts immunosuppressive effects by competing with CD226 for the same ligand CD155. Furthermore, we also show that TIGIT expression and function are not altered in untreated relapsing-remitting MS patients, suggesting that this pathway could potentially be targeted therapeutically to inhibit the hyperactivated status of memory CD4+ T cells in patients. These data provide evidence for a novel role of this alternative costimulatory pathway in regulating human T cell responses associated with autoimmune disease.

Materials and Methods

Cell culture reagents and Abs

Peripheral venous blood was obtained from healthy control volunteers in compliance with Institutional Review Board protocols at Yale University School of Medicine. Total CD4+ T cells were isolated by negative selection (CD4+ T cell isolation kit II; Miltenyi Biotec, Auburn, CA) and sorted on a FACSAria (BD Biosciences, San Jose, CA). Plates (96-well plates in RPMI 1640 medium with 5% human AB serum (Gemini Bio-Products, Woodland, CA). The Abs used for stimulation were anti-CD3 (clone UCHT1) and anti-CD28 (clone 28.2.1) (BD Biosciences) at 1 μg/ml. Recombinant human IL-2 was obtained through the AIDS Research and Reference Reagent Program (Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health) and was used at 10 U/ml.

Abs to human TIGIT (VSTM3) were provided by ZymoGenetics (a wholly-owned subsidiary of Bristol-Myers Squibb) and were generated by immunizing BALB/C mice with soluble human TIGIT protein (14). None of the five mAbs against human TIGIT was capable of blocking the binding of soluble human TIGIT to cells expressing human CD155. However, two of these mAbs showed an agonistic activity measured in T cell proliferation assays (14). For our functional assays, we use the clone 3870 THE TIGIT/CD226 AXIS REGULATES HUMAN T CELL FUNCTION

ELISA

ELISA measurement of IFN-γ and IL-10 were performed with purified coating and biotinylated detection Abs: human IFN-γ mAb (clone 2G1) and human IFN-γ mAb biotin-labeled (Thermo Scientific, Rockford, IL) and rat anti-human and viral IL-10 and biotin anti-human and viral IL-10 (BD Biosciences).

Quantification of mRNA expression levels by real-time PCR

RNA was isolated using a Qiagen RNeasy Micro kit (Qiagen, Valencia, CA) and converted to cDNA by reverse transcription with random hexamers and MultiScribe reverse transcriptase (TaqMan reverse transcription reagents; Applied Biosystems, Foster City, CA). For mRNA gene expression assays, probes were purchased from Applied Biosystems and the reactions run on a 7500 Fast real-time PCR system (Applied Biosystems). To evaluate IL-2 gene expression, memory T cells were incubated in the presence of anti-TIGIT mAb or an isotype control for 2 d (probe Hs_00914135_m1 from Applied Biosystems). Values are represented as the difference in Ct values normalized to β2-microglobulin for each sample as per the following formula: Relative RNA expression = (2^{-ΔCt}) × 1000.

CD226 silencing by small interfering RNA

Predesigned small interfering RNA (siRNA) for human CD226 and a negative control siRNA were obtained from Applied Biosystems. Purified CD4+ T cells (1 × 10⁵) were transfected with either negative control siRNA or CD226 siRNA (S20972) by electroporation using the Nucleofector device (Amxaza). Transfected cells were incubated for 16 h, followed by addition of 20 U/ml human IL-2 and transfer of the cells to a 96-well plate coated with anti-CD3/CD28 mAbs. On days 1 and 2 after transfection, cells were collected for RNA extraction to assess gene expression. On day 3, CD226 surface expression and IFN-γ production were determined.

Lentiviral siRNA knockdown of CD226 and TIGIT

Lentiviruses expressing shRNAs were obtained from the library of The RNAi Consortium (15). We initially tested five different hairpins directed against CD226 and TIGIT and compared their efficiency by real-time PCR against a control hairpin. Targeted sequence are shown in Supplemental Table I; shCD226, shTIGIT-1, and shTIGIT-2 were the most efficient.

Human CD4+ T cells were plated on a 96-well plate at a concentration of 10⁶ cells per well and activated with anti-CD3 and anti-CD28 at 1 μg/ml. After 24 h, the medium was carefully removed, 22 μl virus and 6 μg/ml polybrene were added, and the plate was centrifuged at 2250 rpm for 30 min at room temperature. After centrifugation, all medium was removed and fresh supplemented RPMI 1640 medium was added. After 48 h cells were collected with 2 μg/ml puromycin and collected for analysis 72 h after selection.

Statistical analysis

A standard two-tailed Student t test was used for statistical analysis. A p value of <0.05 was considered statistically significant.

Results

TIGIT, CD155, and CD226 are upregulated on human CD4+ T cells after activation

To investigate the role of TIGIT on T cell function, we began by examining TIGIT expression in human CD4+ T cells ex vivo and after activation with anti-CD3 and anti-CD28 mAbs. As shown in Fig. 1, TIGIT was not expressed on ex vivo naïve T cells (CD4+CD45RO−), but its expression was induced upon stimulation in the CD45RO+ population. Similarly, we confirmed the upregulation of CD226 in both naïve and memory populations. Interestingly, CD155, the ligand for both CD226 and TIGIT, was also induced after activation both on naïve and memory T cells, although there was a higher frequency of CD155+ T cells in the CD45RO+ population (Fig. 1A). We confirmed upregulation of TIGIT, CD226, and CD155 gene expression by real-time RT-PCR on FACS-sorted memory T cells (Fig. 1B). The second ligand for

with a Live/Dead Fixable Dead Cell Stain Kit (Molecular Probes) was performed before fixation to allow gating on viable cells.

Cell activation and intracellular staining

Cell populations were stimulated with anti-CD3, anti-CD28, and IL-2 in the presence of agonistic anti-TIGIT. At day 4, cells were restimulated with PMA (50 ng/ml) and ionomycin (250 ng/ml) for 4 h in the presence of GolgiStop (BD Biosciences). Cells were fixed and made permeable (Foxp3 staining buffer set; eBioscience) and incubated with anti-IFN-γ (clone B27), anti-IL-13 (clone JES10-5A2), anti-IL-4 (clone SD4-8), anti-IL-9 (clone MH9A4), and anti-IL-17 (clone BL168) from BioLegend. Staining

Downloaded from http://www.jimmunol.org/ by guest on April 15, 2017
CD226 and TIGIT, CD112, was not expressed on CD4+ T cells ex vivo and was not upregulated upon activation.

**TIGIT signaling inhibits T cell proliferation**

Because TIGIT contains an ITIM that could trigger a negative regulation of T cell functions, we investigated whether TIGIT can also directly inhibit T cell proliferation. T cells were stimulated in the presence of an agonistic anti-TIGIT mAb (clone 318.28.2.1) for 5 d, and T cell proliferation was assessed by a CFSE dilution assay after gating on viable cells. As depicted in Fig. 2, this agonistic anti-TIGIT mAb efficiently inhibited human CD4+ T cell proliferation (Fig. 2A, 2B). No significant differences were observed in frequency of viable cells (Fig. 2C, 2D). Recently, a new functional Ab against human TIGIT (clone MBSA43) has been generated; when we tested this Ab in the same conditions, we did not find an effect on T cell proliferation, although in certain conditions we observed a slight increase in IFN-γ production (Supplemental Fig. 1). Furthermore, TIGIT ligation did not cause a significant increase in the frequency of early or late apoptotic cells (Supplemental Fig. 1). To address the mechanism by which TIGIT engagement leads to inhibition of proliferation, we evaluated the expression of cell surface markers of activation by flow cytometry. When primary CD4+ T cells were cultured in the presence of agonistic anti-TIGIT (clone 318.28.2.1), they showed decreased expression of CD25 and CD69 as compared with isotype control (Fig. 2E). To exclude the possibility that anti-TIGIT could act on the small percentage of regulatory T cells increasing suppression, we isolated CD4+CD62L+CD45RO−CD25low memory T cells by FACS sorting (Fig. 2F) and repeated proliferation assays excluding any other cell type. We confirmed that TIGIT has an intrinsic inhibitory effect on human memory T cell proliferation (Fig. 2G). To better characterize the mechanism by which TIGIT decreases T cell proliferation, we also quantified the production of IL-2 by real-time PCR. Importantly, IL-2 gene expression was significantly downregulated in the presence of anti-TIGIT (clone 318.28.2.1) (Fig. 2H), consistent with the decrease in TCR signaling after TIGIT ligation. Taken together, these data indicate the engagement of TIGIT by its ligands can deliver an inhibitory signal, resulting in decreased T cell activation, IL-2 production, and TCR-mediated proliferation.

Furthermore, no significant differences were found in TIGIT expression on ex vivo and activated FACS-sorted memory T cells from untreated relapsing-remitting MS patients compared with age-matched healthy donors (Supplemental Fig. 3). In agreement with the results obtained with healthy donor T cells, the inhibitory effects of TIGIT signaling are functional in T cells from MS patients, suggesting that activation of TIGIT signaling may represent a new approach for the treatment of human autoimmune disease.
CD226-specific small interfering RNA (siCD226) effectively re-
expression in human CD4+ T cells transfected with specific siCD226 or negative siRNA, assayed by real-time RT-PCR on
days 1 and 2 after electroporation. (B) Flow cytometry of the surface ex-
pression of CD226 and IFN-γ intracellular staining on human CD4+ T cells transfected with siRNA or control, and stimulated with PMA and
dexamethasone for 4 h in the presence of GolgiStop. Cells were stained with
a Live/Dead Fixable Dead Cell Stain Kit before fixation to allow gating on
viable cells. (C) Measurement of IFN-γ in the supernatants of cells transfected
with siCD226 or negative siRNA. (D) Flow cytometry of the surface expression of CD226 and IFN-γ intracellular staining on CD4+ T cells transfected as in (B) and then stimulated with IL-12 for 3 d. (E) Flow cytometry of the surface expression of CD226 and IFN-γ intracell-
ular staining on human CD4+ T cells transduced with shCD226 or control
by lentiviral transduction. Data are representative of three independent
experiments. Mean values are shown ± SEM.

**FIGURE 4.** Knockdown of CD226 expression in human CD4+ T cells.
(A) CD226 gene expression in human CD4+ T cells transfected with
specific siCD226 or negative siRNA, assessed by real-time RT-PCR on
days 1 and 2 after electroporation. (B) Flow cytometry of the surface ex-
pression of CD226 and IFN-γ intracellular staining on human CD4+ T cells transfected with siRNA or control, and stimulated with PMA and
ionomycin for 4 h in the presence of GolgiStop. Cells were stained with
a Live/Dead Fixable Dead Cell Stain Kit before fixation to allow gating on
viable cells. (C) Measurement of IFN-γ in the supernatants of cells transfected
with siCD226 or negative siRNA. (D) Flow cytometry of the surface expression of CD226 and IFN-γ intracellular staining on CD4+ T cells transfected as in (B) and then stimulated with IL-12 for 3 d. (E) Flow cytometry of the surface expression of CD226 and IFN-γ intracell-
ular staining on human CD4+ T cells transduced with shCD226 or control
by lentiviral transduction. Data are representative of three independent
experiments. Mean values are shown ± SEM.
expression of TIGIT mRNA >80% (Fig. 5A) but not of other negative T cell regulators such as CTLA4 and PD-1 (Fig. 5B).

To determine the effect of knocking down TIGIT expression on cytokine production, we examined the expression of transcription factor T-bet (Tbx21), the master transcription factor that induces IFN-γ production. Knockdown of TIGIT mRNA expression was accompanied by increases in both T-bet and IFN-γ mRNA expression (Fig. 5C). In contrast, deletion of TIGIT resulted in a significant reduction of IL-10 gene expression in cells transduced with both shTIGIT-1 and shTIGIT-2 (Fig. 5C), suggesting a central role of TIGIT in reciprocally regulating proinflammatory (IFN-γ) and anti-inflammatory (IL-10) cytokines.

To confirm these results at the protein level, we stimulated the puromycin-resistant cells with PMA and ionomycin for 4 h and then assayed TIGIT expression and cytokine production by intracellular staining. Consistent with a role of TIGIT in reducing T cell responses, knockdown of TIGIT increased IFN-γ production in cells transduced with both shTIGIT-1 and shTIGIT-2 (Fig. 5D), confirming that TIGIT may act directly by inhibiting IFN-γ production in human T cells. Measurement of IL-10 secretion in transduced CD4+ T cells revealed that depletion of TIGIT was accompanied by a decrease in IL-10 production (Fig. 5E), suggesting a cell-intrinsic role for TIGIT in IL-10 production in the absence of APCs.

**Discussion**

Allelic variants in the TIGIT/CD226 pathway have recently been identified as risk factors for developing human autoimmune dis-
eases (7). However, the mechanisms associated with human CD4+ T cell expression of these receptors are not known. In this study, we demonstrate that engagement of TIGIT with an agonistic mAb triggers a direct inhibitory effect on T cell entry into cell cycle with a decrease in expression of the T-bet, GATA3, IRF4, and RORc transcription factors associated with inhibition of cytokine production, predominantly IFN-γ. TIGIT expression represses T-bet, as knockdown of TIGIT induces T-bet-mediated IFN-γ secretion while decreasing IL-10. The increase in IFN-γ was overcome by blocking CD226 signaling, indicating that TIGIT exerts immunosuppressive effects by competing with CD226 for the CD155 ligand similar to the CD28/CTLA4 pathway. These data provide evidence for a novel role of this alternative costimulatory pathway in differentially regulating proinflammatory (IFN-γ) versus anti-inflammatory (IL-10) cytokine production in a T cell-intrinsic manner.

Our recent investigations in the EAE model of multiple sclerosis have demonstrated a critical role of TIGIT as a negative regulator of autoimmune responses (13). The phenotype of TIGIT-deficient mice includes augmented T cell proliferation upon immunization and higher production of proinflammatory cytokines leading to greater EAE susceptibility (13). These data in the EAE model were confirmed in a collagen-induced arthritis model of arthritis where administration of soluble TIGIT Fc-fusion protein significantly inhibited the severity of disease whereas a blocking anti-TIGIT mAb (10A7) was not agonistic and perhaps recognized a different TIGIT determinant. In another study performed by Levin et al. (14), two of five anti-human TIGIT showed an agonistic effect efficiently inhibiting T cell proliferation. In our investigations, one of these clones was selected for functional assays (clone 318.28.2.1) whereas the others could bind TIGIT but did not show any agonistic effect. Consistent with data reported by Levin et al. (14), we demonstrated that engagement of TIGIT by its ligands can deliver an inhibitory signal resulting in decreased T cell activation, IL-2 production, and TCR-mediated proliferation. Thus, the agonistic function of the TIGIT mAbs in vitro and in vivo in the EAE model suggests its utility therapeutically, particularly with our recent finding of Th1 regulatory T cells in patients with MS where IFN-γ expression inhibits the function of regulatory T cells (16).

The TIGIT-intrinsic mechanism of negative regulation of T cell functions may also have implications in tumor immunology. Similar to PD-1 ligands, TIGIT ligands CD155 and CD112 are overexpressed in certain human tumors, including colorectal carcinomas (17), gastric cancer (18), and neuroblastomas (19). CD226/CD155 interaction has been implicated as a major trigger for NK cell antitumor activity (20), whereas TIGIT/CD155 interaction inhibits NK cell cytotoxicity (21). However, the role of TIGIT in tumor settings remains to be elucidated. Our data demonstrate that TIGIT is critical for the regulation of lymphocyte function and can efficiently limit T cell-dependent immune responses. This mechanism may enable tumors overexpressing CD155 to escape from immune attack. The clinical relevance of modulation of a negative regulator to augment immune responses directed at tumors has been recently proved with the generation of an Ab against CTLA4 (ipilimumab) that enhances immune activation against cancer cells, resulting in significant antitumor effects (22).

In this study, we demonstrated that TIGIT signaling could also directly inhibit T cell activation by a second mechanism where TIGIT acts as negative regulator by competing with CD226 for binding to its ligand CD155 to inhibit T cell responses. This new costimulatory pathway is similar to the CD28/CTLA4 pathway that binds to B7-1 (CD80) and B7-2 (CD86) ligands. Interestingly, CTLA4 interacts with at least 20-fold higher avidity than CD28 does (23). In a similar manner, TIGIT is a negative regulator that binds CD155 with higher affinity (119 nM) compared with the CD226/CD155 interaction (1–3 nM) (12). Therefore, once expressed, TIGIT can effectively compete for binding to the same CD155 ligand similar to CD28/CTLA4 interactions with B7-1/B7-2. In this regard, therapies based on interfering with the costimulatory CTLA4 pathway have recently been approved for clinical use. Specifically, a CTLA4 fusion protein (abatacept) has been approved to treat rheumatoid arthritis (24). Thus, the TIGIT/CD226 pathway is an attractive target for therapeutic manipulation.

In addition to its immunosuppressive effects on DCs, in this study we demonstrate that TIGIT exerts multiple mechanisms of peripheral tolerance: 1) the direct inhibition of T cell proliferation and production of proinflammatory cytokines; 2) induction of anti-inflammatory cytokines such as IL-10; and 3) the blockade of CD226-positive costimulatory signaling. To better understand the role of each receptor in this complex network, we performed these experiments in the absence of APCs. Given that T cells can express CD155 but not CD112, we can exclude that the observed effects are due to CD112 signaling. To dissect the underlying molecular mechanisms of this regulatory pathway, we first downregulated CD226 expression on human T cells and observed a decrease in T-bet expression and IFN-γ production. This result is consistent with previous reports showing that introduction of mutant (Y-F322) CD226 into naive CD4+ T cells suppresses their growth initiated by CD3 and LFA-1 ligation in the absence of IL-2, suggesting that CD226 functions as a signal transducer of LFA-1 upon triggering T cell activation (9). When we specifically knocked down TIGIT expression, we obtained the opposite results: an increase in T-bet and IFN-γ expression, consistent with the inhibitory effects triggered by the agonistic anti-TIGIT mAb. These data demonstrate that TIGIT ligation initiates a negative signaling cascade and by blocking CD226 or CD155 in TIGIT-depleted cells, and the increases in IFN-γ production are due to an enhanced CD226/CD155 interaction.

Interestingly, lack of TIGIT resulted in a decrease in IL-10 production. Accordingly, studies in TIGIT−/− mice showed that IL-10 was not induced by Ag-specific stimulation in TIGIT−/− T cell cultures, suggesting that production of IL-10 by T cells was impaired (13). One possible explanation for this defect in IL-10 production could be that TIGIT signaling directly activates IL-10 production but agonistic anti-TIGIT mAb failed to increase IL-10 expression (data not shown). Alternatively, in the absence of TIGIT, CD226 can interact with CD155, increasing IFN-γ while repressing IL-10 gene expression. However, blocking CD226/CD155 interaction did not increase IL-10 expression. It has been reported that TIGIT, through its interaction with CD155, can modulate Erk activity and increase IL-10 production by DCs (12). It is intriguing to speculate that T cells expressing CD155 might be regulated in a similar manner and thus TIGIT depletion impaired IL-10 production by CD155-expressing T cells.

TIGIT/CD226 pathway is a novel regulatory pathway of T cell function associated with human autoimmune disease. Manipula-
tion of the TIGIT/CD226 axis in vitro regulated T cell function by cell-intrinsic and cell-extrinsic mechanisms. To examine the potential therapeutic intervention of this pathway in patients with autoimmune diseases, we demonstrate that TIGIT expression is not altered in untreated relapsing-remitting MS patients and that an agonistic Ab to TIGIT has an inhibitory effect on CD4^+ T cells from MS patients. Although further studies are needed to test the therapeutic benefits of targeting inhibitory pathways, modulation of the TIGIT/CD226 axis may allow more targeted manipulation of human CD4^+ T cells in autoimmune diseases.

Acknowledgments
We thank the blood donors and MS patients for participation. Abs to human TIGIT were provided by ZymoGenetics/Bristol-Myers Squibb under a Material Transfer Agreement.

Disclosures
The authors have no financial conflicts of interest.

References

Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved.

Downloaded from http://www.jimmunol.org/ by guest on April 15, 2017